title: Immunological effects of in vivo interferon-beta1b treatment in ten patients with multiple sclerosis: a 1-year follow-up.
abstract: Ten patients with multiple sclerosis and treated with interferon-beta1b (IFN-beta1b) were followed-up for 1 year with quantitation of serum VCAM-1 and ICAM-1 levels, mean fluorescence intensity of HLA-DR, VLA-4, CD11a, and CD18 on peripheral blood monocytes and lymphocytes, and adhesion of peripheral blood monocytes and CD45+ cells on endothelial cell monolayers. Adhesion molecule expression and adhesion of peripheral blood monocytes to endothelium were also monitored in healthy controls. No differences in adhesion were detected between MS patients before treatment and healthy controls, while after 1 year a marked decrease in the number of monocytes and mononuclear cells adhering to human umbilical vein endothelial cell monolayers was observed in patients treated with IFN-beta1b. After 1 year of treatment a significant increase in HLA-DR on peripheral blood monocytes was also detected. Our findings regarding lowered adhesion add information to available evidence of the mechanisms of action of IFN-beta1b in MS.
authors.affiliation: Istituto Nazionale Neurologico C. Besta, Milan, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Gelati
authors.forename: E
authors.initials: E
authors.lastname: Corsini
authors.forename: A
authors.initials: A
authors.lastname: Dufour
authors.forename: G
authors.initials: G
authors.lastname: Massa
authors.forename: L
authors.initials: L
authors.lastname: La Mantia
authors.forename: C
authors.initials: C
authors.lastname: Milanese
authors.forename: A
authors.initials: A
authors.lastname: Nespolo
authors.forename: A
authors.initials: A
authors.lastname: Salmaggi
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology / Q000627:therapeutic use*; D000328:Adult; D018821:CD18 Antigens / Q000032:analysis; D002448:Cell Adhesion / Q000187:drug effects / Q000502:physiology; D005260:Female; D005500:Follow-Up Studies; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D039041:Integrin alpha4beta1; D016023:Integrins / Q000032:analysis; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood; D016899:Interferon-beta / Q000494:pharmacology / Q000627:therapeutic use*; D016169:Lymphocyte Function-Associated Antigen-1 / Q000032:analysis; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D016201:Receptors, Lymphocyte Homing / Q000032:analysis; D019010:Vascular Cell Adhesion Molecule-1 / Q000097:blood
chemical_list: D000276:Adjuvants, Immunologic; D018821:CD18 Antigens; D006684:HLA-DR Antigens; D039041:Integrin alpha4beta1; D016023:Integrins; D016169:Lymphocyte Function-Associated Antigen-1; D016201:Receptors, Lymphocyte Homing; D019010:Vascular Cell Adhesion Molecule-1; D018799:Intercellular Adhesion Molecule-1; D016899:Interferon-beta